Impact of the faecal immunochemical test on colorectal cancer survival
BMC Cancer Jul 05, 2020
Gutierrez-Stampa MA, Aguilar V, Sarasqueta C, et al. - Researchers investigated if a higher survival would be reported in colorectal cancer (CRC) patients if they have been first diagnosed by faecal immunochemical test (FIT) (vs the rest of patients with CRC). Symptomatic patients were the main focus. CRC cases were split into two groups depending on the route to diagnosis: people who tested positive in a FIT during the year prior to diagnosis (group 1), and group 2 included others. The group 1 was identified to have higher rate of early-stage disease (stage I or II). A longer 3-year survival was reported in group 1. Group 2, age > 70 years and stage at the moment of diagnosis, all were identified as variables that were independently related to worse survival. Overall, based on the findings, experts concluded that an improved survival in CRC may be achieved by using FIT as a diagnostic strategy in symptomatic patients. Nonetheless, FIT is still not broadly employed in experts' region.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries